Genmab A/S (GNMSF) Total Liabilities (2019 - 2026)
Genmab A's (GNMSF) quarterly Total Liabilities came in at $6.7 billion in Q1 2026, up 1.64% YoY from $6.6 billion in Q1 2025, and down 4.73% on a QoQ basis from $7.0 billion in Q4 2025.
Genmab A/S (GNMSF) Total Liabilities (2019 - 2026) Analysis & Trends
Genmab A (GNMSF) has 6 years of Total Liabilities data on file, last reported at $6.7 billion in Q1 2026.
- Quarterly Total Liabilities rose 1.64% year-over-year to $6.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.7 billion (up 1.64% YoY) and the FY2025 annual result came in at $7.0 billion, up 450.2% from the prior year.
- Total Liabilities eased to $6.7 billion in Q1 2026, from $7.0 billion in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $7.0 billion in Q4 2025 to a low of $545.0 million in Q4 2023.
- A 4-year average of $3.5 billion and a median of $1.3 billion in 2024 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2025 — Total Liabilities jumped 450.2% — and 2026, when it advanced 1.64%.
- Tracing GNMSF's Total Liabilities over 4 years: stood at $545.0 million in 2023, then jumped by 134.31% to $1.3 billion in 2024, then jumped by 450.2% to $7.0 billion in 2025, then dropped by 4.73% to $6.7 billion in 2026.
- The last three Total Liabilities figures came in at $6.7 billion (Q1 2026), $7.0 billion (Q4 2025), and $1.3 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.56 Bn |
| Mar 31, 2026 | 6.69 Bn |
| Dec 31, 2025 | 7.03 Bn |
| Sep 30, 2025 | 1.27 Bn |
| Jun 30, 2025 | 1.16 Bn |
| Mar 31, 2025 | 6.59 Bn |
| Dec 31, 2024 | 1.28 Bn |
| Dec 31, 2023 | 545.00 Mn |
| Sep 30, 2020 | 3,045,000.00 Bn |
| Dec 31, 2019 | 1,096,000.00 Bn |
| Sep 30, 2019 | 815.67 Mn |